Industry

Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The … [Read more…]

Total revenues of $185.1 million, up 10% year-over-year Net income of $61.6 million, margin of 33% Adjusted EBITDA of $111.4 million, margin of 60% SAN FRANCISCO–(BUSINESS WIRE)–Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2026 third quarter ended December 31, 2025. “We’re proud to deliver … [Read more…]

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared to placebo, both in combination with antiplatelet therapy These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–#biotechshowcase–As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year, the event continued to distinguish itself as a leading hub for early-stage biotechnology companies seeking meaningful visibility, strategic dialogue, and access to private investment. Held alongside the J.P. Morgan Healthcare Conference, Biotech Showcase facilitated 6,000 partnering and investment meetings, complemented by more … [Read more…]

Visit Vektor Medical at Booth 208 to Learn More about vMap®, the VITAL-EP Registry’s AF Findings, and the Newly Released Atrial Flutter Workflow BOSTON–(BUSINESS WIRE)–#AFSymposium2026—Vektor Medical, a medical technology company transforming cardiac arrhythmia care, today announced its participation in AF Symposium 2026, taking place February 5–8 in Boston, where new clinical data and physician experiences … [Read more…]

SAN SEBASTIAN, Spain–(BUSINESS WIRE)–#HPC–Quantum Motion today announced the opening of its offices in Spain, establishing a permanent base for quantum system development, integration and deployment in the European Union. The new site, which is located in the newly inaugurated nanoGUNE Quantum Tower, supports Quantum Motion’s scale-up of silicon-based quantum computing systems and strengthens the collaboration … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat® KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) … [Read more…]

– Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo®, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology – HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced the presentation of four datasets demonstrating the potential benefits of its investigational therapies for … [Read more…]

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general … [Read more…]

NEW YORK–(BUSINESS WIRE)–Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company’s common stock … [Read more…]